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Background: In the current analysis, we characterize the prognostic significance of KRAS mutations 
with concomitant copy number aberrations (CNA) in early stage non-small cell lung cancer (NSCLC), and 
evaluate the ability to predict survival benefit from adjuvant chemotherapy. 
Methods: Clinical and genomic data from the LACE (Lung Adjuvant Cisplatin Evaluation)-Bio 
consortium was utilized. CNAs were categorized as Gain (CN ≥2) or Neutral (Neut)/Loss; KRAS status 
was defined as wild type (WT) or mutant (MUT). The following groups were compared in all patients and 
the adenocarcinoma subgroup, and were correlated to survival endpoints using a Cox proportional hazards 
model: WT + Neut/Loss (reference), WT + Gain, MUT + Gain and MUT + Neut/Loss. A treatment-by-
variable interaction was added to evaluate predictive effect. 
Results: Of the 946 (399 adenocarcinoma) NSCLC patients, 41 [30] had MUT + Gain, 145 [99] MUT + 
Neut/Loss, 125 [16] WT + Gain, and 635 [254] WT + Neut/Loss. A non-significant trend towards worse 
lung cancer-specific survival (LCSS; HR =1.34; 95% CI, 0.83–2.17, P=0.232), DFS (HR =1.34; 95% CI, 
0.86–2.09, P=0.202) and OS (HR =1.59; 95% CI, 0.99–2.54, P=0.055) was seen in KRAS MUT + Gain 
patients relative to KRAS WT + Neut/Loss patients. A negative prognostic effect of KRAS MUT + Neut/
Loss was observed for LCSS (HR =1.32; 95% CI, 1.01–1.71, P=0.038) relative to KRAS WT + Neut/Loss 
on univariable analysis, but to a lesser extent after adjusting for covariates (HR =1.28; 95% CI, 0.97–1.68, 
P=0.078). KRAS MUT + Gain was associated with a greater beneficial effect of chemotherapy on DFS 
compared to KRAS WT + Neut/Loss patients (rHR =0.33; 95% CI, 0.11–0.99, P=0.048), with a non-
significant trend also seen for LCSS (rHR =0.41; 95% CI, 0.13–1.33, P=0.138) and OS (rHR =0.40; 95% CI, 
0.13–1.26, P=0.116) in the adenocarcinoma subgroup. 
Conclusions: A small prognostic effect of KRAS mutation was identified for LCSS, and a trend towards 
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Introduction
Advances in next generation sequencing have led to the 
identification of molecular alterations in non-small cell lung 
cancer (NSCLC), including mutations, fusions, increased 
tumor mutation burden, and copy number aberrations 
(CNA), among others. However, understanding the 
complex genetic landscape in NSCLC remains challenging, 
as only a small proportion of these alterations likely have 
clinical significance. 
Previous LACE-Bio studies evaluated the prognostic and 
predictive role of KRAS mutations, and KRAS/TP53 co-
mutations in early stage NSCLC (1,2). No clear prognostic 
or predictive role was detected, although a potentially 
negative predictive effect of TP53/KRAS co-mutation (2), 
and a possible deleterious effect of adjuvant chemotherapy 
in patients with a KRAS codon-13 mutation require further 
investigation (1). The KRAS oncogene is mutated frequently 
in NSCLC, particularly adenocarcinoma (3-5); however, 
the clinical impact of KRAS CNAs is unclear. Evaluation of 
the genome of primary lung adenocarcinomas by Weir et al. 
revealed areas of copy number amplification at 12p12.1, a 
region known to harbor the KRAS oncogene (6). Likewise, 
characterization of gene CNAs in resected NSCLC by the 
LACE-Bio consortium showed KRAS copy number gains; 
however, no significant association between KRAS CNA 
and survival was observed (7). 
Few studies have shown that KRAS copy number gain 
might be associated with the presence of concomitant 
KRAS mutations (6,8,9). For instance, Modrek et al. showed 
that KRAS-mutated tumors appeared to have higher copy 
number compared to wild type (WT) tumors, with distinct 
patterns of gain across chromosome 12 (9). Moreover, even 
moderate KRAS copy number gains have been associated 
with increases in KRAS mRNA expression (8,9). 
The prognostic and predictive role of concomitant KRAS 
mutations and CNA has not been well elucidated. Sasaki 
et al. showed that NSCLC patients with KRAS mutated 
tumors and increased copy number had worse prognosis 
compared to those with KRAS WT tumors with no increase 
in copy number; however, their study was limited by a small 
number of patients (10). In the current study, we completed 
a pooled analysis of LACE-Bio data to characterize the 
prognostic effect of KRAS mutation status and concomitant 
CN gain in early stage NSCLC, and to determine the ability 
to predict survival benefit from adjuvant chemotherapy. We 
hypothesized that concomitant KRAS mutations and CN 
gain would be prognostic of worse survival compared to 
KRAS mutations alone and that patients with mutation and 
CN gain might have the greatest potential to benefit from 
adjuvant chemotherapy.
We present the following article in accordance with the 




The LACE (Lung Adjuvant Cisplatin Evaluation)-Bio 
group conducts meta-analyses of data from 3 adjuvant 
randomized clinical trials [JBR.10, IALT (International 
Adjuvant Lung Cancer Trial), ANITA (Adjuvant Navelbine 
International Trialist Association)] comparing cisplatin-
based chemotherapy versus observation, and CALGB-9633, 
which compared carboplatin-based chemotherapy versus 
observation (11-16). The LACE-Bio collaboration 
includes bio-banked tissue samples prospectively collected 
from JBR.10 and CALGB-9633, as well as retrospective 
samples from the IALT group (7,17). In this study, clinical 
and genomic data from the LACE-Bio consortium were 
used to evaluate the prognostic and predictive effect of 
concomitant KRAS mutation and gene CNAs in early stage 
NSCLC patients. All procedures performed in this study 
were in accordance with the Declaration of Helsinki (as 
revised in 2013).
worse LCSS, DFS and OS was noted for KRAS MUT + Gain. A potential predictive effect of concomitant 
KRAS mutation and copy number gain was observed for DFS in adenocarcinoma patients. These results 
could be driven by the small number of patients and require validation.
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KRAS gene copy number and mutation analyses
DNA extracted from formalin-fixed and paraffin-
embedded (FFPE) sections was used for KRAS mutation 
and genome-wide copy number analyses using methods 
previously described (1,7). Briefly, KRAS mutation analyses 
were completed using allelic specific oligonucleotide 
hybridization with sequencing confirmation in JBR.10, 
and PCR amplification and direct sequencing of exon 
2 in IALT and CALGB-9633 (1). Whole-genome copy 
number analyses were completed using the OncoScan 
CNV Plus Assay (ThermoFisher, Carlsbad, California, 
USA) (7). CNAs were categorized into two groups: Gain 
(2-fold higher CN) or Neutral (Neut)/Loss; and KRAS 
mutation status was defined as WT or mutant (MUT). The 
following groups were compared in all patients and the 
adenocarcinoma subgroup: WT + Neut/Loss (reference), 
WT + Gain, MUT + Gain, MUT + Neut/Loss.
Outcomes
The primary endpoint was lung cancer-specific survival 
(LCSS), defined as the time from randomization to death 
from lung cancer, censoring at the date of death from other 
causes and without lung cancer recurrence. Secondary 
endpoints included disease free survival (DFS), defined 
as the time from randomization to the time of first event 
(recurrence or death from any cause); and overall survival 
(OS), defined as the time from randomization to the date of 
death from any cause. Patients for whom no events had been 
observed were censored at the date of their last follow-up. 
Statistical analysis
The Kaplan-Meier method and log-rank test were used to 
compare survival curves between the four groups mentioned 
above. KRAS mutation status, and concomitant KRAS CNA 
and mutational status were separately correlated to survival 
endpoints using a Cox proportional hazards model, which 
was stratified by trial in all models, adjusted for treatment 
in the unadjusted model, and adjusted for treatment, age, 
sex, tumor stage, nodal stage, histology, WHO performance 
status and surgery type in the fully adjusted model. For 
KRAS mutation status, the WT group was the reference 
category, and the HR was reported for MUT versus WT 
group. For the concomitant KRAS CNA and mutation 
status, WT + Neut/Loss was the reference category, and 
the HR for a given category (MUT + Gain, MUT + Neut/
Loss or WT + Gain) was interpreted as the relative hazard 
for that category versus the WT + Neut/Loss category. To 
evaluate the predictive role of concomitant KRAS CNA 
and mutation status, a treatment-by-variable interaction 
was added to the Cox models stratified by study. For each 
endpoint, we compared the treatment effect across four 
concomitant KRAS CNA and mutation status groups by 
using the ratio of HRs (rHR): the ratio of the HR for 
adjuvant chemotherapy versus observation in a given 
category ‘c’ (MUT + Gain, MUT + Neut/Loss or WT 
+ Gain) to the HR for adjuvant chemotherapy versus 
observation in the WT + Neut/Loss category (rHR = 
HR(Chemo vs. Obs. in c)/HR(Chemo vs. Obs. in WT + 
Neut/Loss)). A rHR <1.0 indicates that the treatment effect 
size was greater for category ‘c’ than for WT + Neut/Loss 
patients. Given that KRAS mutations occur primarily in 
the adenocarcinoma group, analyses were also performed 
separately for this subtype. Statistical significance was set 
at P<0.05. All statistical analyses were performed using 




A total of 946 patients had complete clinical data including 
both KRAS mutation and CNA results (Figure 1): 41 MUT 
+ Gain, 145 MUT + Neut/Loss, 125 WT + Gain, and 
635 WT + Neut/Loss (reference group). There were 399 
patients in the adenocarcinoma subgroup, with 30 MUT 
+ Gain, 99 MUT + Neut/Loss, 16 WT + Gain, and 254 
WT + Neut/Loss. The most common KRAS mutation 
subtypes were KRAS G12C (n=89; 47.8%), G12V (n=44; 
23.6%) and G12D (n=18; 9.7%) (Table S1). Baseline patient 
characteristics for the total population are summarized 
in Table 1. Almost half of the patients were older than 60 
years of age, with the majority (72.52%) being male. Data 
regarding smoking history were collected in the JBR.10 and 
CALGB-9633 trials, and summarized in Supplementary 
Table 2. Of these 440 patients, 397 (90.2%) were current/
former smokers. Moreover, all KRAS MUT + Gain patients 
(n=25) were current/formers smokers (Tables S2,S3). 
Staging included 46.62% with stage I, 36.89% stage II 
and 16.49% stage III. There was a similar proportion of 
patients with adenocarcinoma (42.18%) and squamous cell 
carcinoma (44.08%). Adjuvant chemotherapy was given to 
half of patients. There were no significant differences in 
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Figure 1 Consort diagram of all patients with complete clinical data, as well as KRAS mutational status and CNA data. CNA, copy number 
aberrations.
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WT + Gain (N=125) MUT+ Gain (N=41)
MUT + Neut/Loss 
(N=145)
Total (N=946)
N % N % N % N % N %
Age
≤50 96 15.12 22 17.60 13 31.71 31 21.38 162 17.13
51–60 225 35.43 37 29.60 11 26.83 55 37.93 328 34.67
>60 314 49.45 66 52.80 17 41.46 59 40.69 456 48.20
Sex
Male 467 73.54 105 84.00 26 63.41 88 60.69 686 72.52
Female 168 26.46 20 16.00 15 36.59 57 39.31 260 27.48
T-stage*
T1 79 12.44 11 8.80 4 9.75 20 13 .79 114 12.05
T2 468 73.70 99 79.20 35 85.37 119 82.07 721 76.22
T3/4 88 13.86 15 12.00 2 4.88 6 4.14 111 11.73
N-stage*
N0 325 51.18 57 45.60 23 56.10 82 56.55 487 51.48
N1 221 34.80 50 40.00 15 36.58 49 33.79 335 35.41
N2 89 14.02 18 14.40 3 7.32 14 9.66 124 13.11
Stage*
I 291 45.83 51 40.80 22 53.66 77 53.10 441 46.62
II 230 36.22 50 40.00 15 36.58 54 37.24 349 36.89
III 114 17.95 24 19.20 4 9.76 14 9.66 156 16.49
WHO Performance 
status
0 328 51.65 55 44.00 21 51.22 80 55.17 484 51.16
≥1 307 48.35 70 56.00 20 48.78 65 44.83 462 48.84
Histology
Squamous 302 47.56 92 73.60 4 9.76 19 13.10 417 44.08
Adenocarcinoma 254 40.00 16 12.80 30 73.17 99 68.28 399 42.18
Other NSCLC 79 12.44 17 13.60 7 17.07 27 18.62 130 13.74
Treatment
Observation 328 51.65 60 48.00 14 34.15 70 48.28 472 49.89
Adjuvant 
chemotherapy
307 48.35 65 52.00 27 65.85 75 51.72 474 50.11
*, 6th Edition TNM Staging classification. NSCLC, non-small cell lung cancer; CNA, copy number aberration; WT, wild type; MUT, mutant; 
WHO, World Health Organization.
831Translational Lung Cancer Research, Vol 10, No 2 February 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(2):826-838 | http://dx.doi.org/ 10.21037/tlcr-20-927
Table 2 Prognostic effect of KRAS mutation and copy number status on patient outcome in the total population (n=946) 
KRAS mutation and CNA
LCSS DFS OS
HR [95% CI], P value HR [95% CI], P value HR [95% CI], P value
Unadjusted model
KRASMUT, n=186 1.31 [1.04–1.66], 0.023 1.18 [0.94–1.47], 0.145 1.11 [0.87–1.40], 0.406
KRASWT, n=760 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=41 1.42 [0.89–2.27], 0.140 1.34 [0.86–2.06], 0.192 1.39 [0.88–2.19], 0.163
KRASMUT + Neut/Loss, n=145 1.32 [1.01–1.71], 0.038 1.13 [0.88–1.45], 0.326 1.03 [0.79–1.34], 0.841
KRASWT + Gain, n=125 1.11 [0.84–1.48], 0.463 0.96 [0.73–1.26], 0.770 0.92 [0.69–1.23], 0.567
KRASWT + Neut/Loss, n=635 (reference) 1.00 1.00 1.00
Fully adjusted model
KRASMUT, n=186 1.27 [0.98–1.63], 0.065 1.18 [0.93–1.49], 0.180 1.18 [0.91–1.52], 0.212
KRASWT, n=760 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=41 1.34 [0.83–2.17], 0.232 1.34 [0.86–2.09], 0.202 1.59 [0.99–2.54], 0.055
KRASMUT + Neut/Loss, n=145 1.28 [0.97–1.68], 0.078 1.14 [0.88–1.47], 0.333 1.08 [0.82–1.42], 0.597
KRASWT + Gain, n=125 1.19 [0.88–1.60], 0.256 0.99 [0.75–1.31], 0.946 0.88 [0.65–1.19], 0.412
KRASWT + Neut/Loss, n=635 (reference) 1.00 1.00 1.00
HR, hazard ratio; CI, confidence interval; CNA, copy number aberration; LCSS, lung cancer specific survival; DFS, disease free survival; 
OS, overall survival; WT, Wild-type; KRASMUT, KRAS mutant; Gain, copy number gain; Neut/Loss, copy number neutral/loss.
baseline patient or tumor characteristics among the four 
subgroups.
Prognostic effect
Kaplan-Meier analyses showed no significant differences 
in terms of LCSS, DFS or OS among the four groups 
based on KRAS CNAs and mutational status in the total 
population (Figure 2), or in the adenocarcinoma subgroup 
(data not shown). Univariable analyses showed that KRAS 
MUT and KRAS MUT + Neut/Loss were associated with 
poor LCSS outcome: the hazard ratio for patients with a 
KRAS MUT was 1.31 (95% CI, 1.04–1.66, P=0.023) relative 
to the KRAS WT group, and the hazard ratio for patients 
with KRAS MUT + Neut/Loss was 1.32 (95% CI, 1.01–1.71, 
P=0.038) relative to the KRAS WT + Neut/Loss category 
(Table 2). However, this was no longer significant after 
adjusting for clinical covariates (KRAS MUT HR =1.27; 
95% CI, 0.98–1.63, P=0.065; and KRAS MUT + Neut/Loss 
HR =1.28; 95% CI, 0.97–1.68, P=0.078, respectively) (Table 
2). In both univariable and multivariable analyses including 
all patients, the worst outcomes consistently were observed 
in the KRAS MUT + Gain subgroup for LCSS (HR =1.34; 
95% CI, 0.83–2.17, P=0.23), DFS (HR =1.34; 95% CI, 
0.86–2.09, P=0.20,) and OS (HR =1.59; 95% CI, 0.99–2.54, 
P=0.055), compared to WT + Neut/Loss (Table 2). When 
limiting analyses to KRAS MUT + Gain compared directly 
to KRAS WT + Neut/Loss, there was a significant negative 
prognostic effect of KRAS MUT + Gain for OS (HR =1.66; 
95% CI, 1.03–2.67, P=0.037; Table 3).
In the adenocarcinoma subgroup, there was no 
significant prognostic effect of KRAS mutation and CNA 
on LCSS, DFS or OS (Table S4). However, there was 
a non-significant trend towards worse OS (HR =1.51; 
95% CI, 0.84–2.72, P=0.169) when KRAS MUT + Gain 
was compared directly to KRAS WT + Neut/Loss in 
adenocarcinoma patients (results not shown). 
Predictive effect
Results of the univariable and multivariable analysis did not 
show any significant predictive effect of KRAS CNA and 
mutation status in the overall population (Figure 3A,B,C and 
Table 4) (interaction P=0.829, 0.670 and 0.579 for LCSS, 
DFS and OS, respectively, in multivariable analysis). In the 
adenocarcinoma subgroup, univariable analysis showed a 
832 Fung et al. KRAS mutation and CNAs in early stage NSCLC
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(2):826-838 | http://dx.doi.org/ 10.21037/tlcr-20-927
Figure 2 Unadjusted Kaplan-Meier survival curves comparing the prognostic effect of MUT + Gain, MUT + Neut/Loss, WT + Gain, and 
WT + Neut/Loss for (A) Lung-cancer-specific survival, (B) Disease-free survival and (C) Overall survival in the total population. MUT, 
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Table 3 Prognostic effect of KRAS mutation and copy number status on patient outcome, limited to the KRAS MUT + Gain and WT + Neut/Loss 
population (fully adjusted models)
KRAS mutation and CNA
LCSS DFS OS
HR [95% CI], P value HR [95% CI], P value HR [95% CI], P value
KRASMUT + Gain, n=41 1.33 [0.81–2.16], 0.255 1.37 [0.87–2.14], 0.171 1.66 [1.03–2.67], 0.037
KRASWT + Neut/Loss, n=635 (reference) 1.00 1.00 1.00
Figure 3 Unadjusted Kaplan-Meier survival curves for (A) Lung-cancer-specific survival, (B) Disease-free survival and (C) Overall survival 
in all KRAS MUT + Gain patients by treatment arm (control, blue; chemotherapy, red), as well as (D) Lung-cancer-specific survival, (E) 














0                1000            2000            3000
0                1000            2000            3000
0                1000            2000            3000
0                1000            2000            3000
0                1000            2000            3000
0                1000            2000            3000
27                 15                 7                   2
18                 12                 6                   2 18                 12                 6                   2 18                12                  6                   2
27                 15                 7                   2 27                 16                 7                   2
14                  3                  1                   0
12                  2                  1                   0 12                  2                  1                   0 12                 3                   2                   0








































































































































Number at risk 







significant predictive effect of KRAS CNA and mutational 
status for OS (interaction P=0.038), although this was no 
longer significant after adjusting for clinical covariates 
(interaction P=0.076; Table 5). However, there appeared 
to be a beneficial effect of chemotherapy on DFS and OS 
based on Kaplan-Meier analysis in KRAS MUT + Gain 
adenocarcinoma patients when compared to observation 
(Figure 3D,E,F). 
In addition, univariable Cox regression models in the 
adenocarcinoma population showed that the beneficial 
effect of chemotherapy on DFS was significantly more 
pronounced for the KRAS MUT + Gain group compared to 
WT + Neut/Loss patients (rHR =0.32; 95% CI, 0.11–0.94, 
P=0.039), with non-significant trends for better LCSS (rHR 
=0.44; 95% CI, 0.14–1.39, P=0.161) and OS (rHR =0.33; 
95% CI, 0.11–1.03, P=0.057). Similarly, multivariable 
analysis showed a significantly higher treatment effect 
size in KRAS MUT + Gain patients for DFS (rHR =0.33; 
95% CI, 0.11–0.99, P=0.048) in adenocarcinoma patients 
(Table 5), with a non-significant trend also seen for LCSS 
Time (days) Time (days)
Time (days) Time (days) Time (days)
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Table 4 Predictive effect of KRAS mutation and copy number status on patient outcome in the total population (n=946)
KRAS mutation and CNA
LCSS DFS OS
rHR [95% CI], P value P value* rHR [95% CI], P value P value* rHR [95% CI], P value P value*
Unadjusted Model
KRASMUT, n=186 1.15 [0.72–1.83], 0.559 0.559 1.05 [0.68–1.63], 0.828 0.828 1.21 [0.75–1.93], 0.435 0.435
KRASWT, n=760 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=41 0.80 [0.30–2.11], 0.653 0.716 0.62 [0.26–1.49], 0.281 0.558 0.61 [0.24–1.53], 0.291 0.360
KRASMUT + Neut/Loss, 
n=145
1.28 [0.76–2.16], 0.350 1.20 [0.73–1.97], 0.722 1.41 [0.83–2.40], 0.203
KRASWT + Gain, n=125 1.71 [0.66–2.07], 0.588 1.15 [0.67–1.98], 0.390 1.18 [0.66–2.12], 0.569




KRASMUT, n=186 1.06 [0.66–1.70], 0.795 0.795 0.98 [0.63–1.53], 0.934 0.934 1.16 [0.72–1.86], 0.552 0.552
KRASWT, n=760 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=41 0.92 [0.35–2.43], 0.861 0.829 0.70 [0.29–1.71], 0.439 0.670 0.73 [0.29–1.84], 0.501 0.579
KRASMUT + Neut/Loss, 
n=145
1.15 [0.68–1.95], 0.600 1.09 [0.66–1.80], 0.722 1.30 [0.76–2.22], 0.341
KRASWT + Gain, n=125 1.27 [0.71–2.26], 0.420 1.27 [0.74–2.19], 0.390 1.26 [0.70–2.26], 0.445
KRASWT + Neut/Loss, 
n=635 (reference)
1.00 1.00 1.00
*, interaction between variable and treatment. rHR, ratio of Hazard Ratio (rHR = HR(Chemo vs. Obs. in c)/HR(Chemo vs. Obs. in reference)); CNA, copy number 
aberration; CI, Confidence interval; LCSS, Lung cancer specific survival; DFS, disease free survival; OS, overall survival; WT, Wild-type; 
KRASMUT, KRAS mutant; Gain, copy number gain; Neut/Loss, copy number neutral/loss.
(rHR =0.41; 95% CI, 0.13–1.33, P=0.138) and OS 
(rHR =0.40; 95% CI, 0.13– 1.26, P=0.116). Similar trends 
were also noted in the total population (Table 4), with a 
suggestion of more benefit to improve DFS (rHR =0.70; 
95% CI, 0.29–1.71, P=0.439) and OS (rHR =0.73; 95% 
CI, 0.29–1.84, P=0.501) with adjuvant chemotherapy in 
the KRAS MUT + Gain group relative to WT + Neut/
Loss patients; this higher benefit was likely driven by the 
adenocarcinoma subset.  
Discussion
The KRAS oncogene frequently is mutated in NSCLC, 
pa r t i cu l a r l y  adenoca rc inoma ,  and  the  b io log i c 
heterogeneity of KRAS-mutated lung cancer has been well 
characterized. The majority of KRAS mutations occur at 
codon 12 (18), and different KRAS point mutations are 
associated with diversity in biological behavior, response to 
therapy, and clinical outcome (5). However, the role of gene 
CNAs in KRAS-mutated tumors is not as well characterized. 
A correlation between KRAS mutations and copy number 
gain has been reported in NSCLC (6,8,9); however, these 
studies have been limited by small numbers of patients. A 
study by Modrek et al. found concomitant KRAS mutations 
and copy number gain in 11 out of 166 (6.6%) NSCLC 
patients (9). Likewise, Sasaki et al. evaluated 172 surgical 
tissue samples from NSCLC patients and identified 8 
patients (4.6%) with concomitant KRAS mutation and 
gene copy number gain (10). In our pooled analysis of 
946 patients, we were able to identify 41 patients (4.3%) 
in the total population who had a KRAS mutation with 
concomitant copy number gain, which is consistent with 
835Translational Lung Cancer Research, Vol 10, No 2 February 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(2):826-838 | http://dx.doi.org/ 10.21037/tlcr-20-927
previous reports. Overall, the proportion of patients who 
harbor concomitant KRAS mutation and copy number gain 
is quite small (approximately 4–6%), suggesting that this is 
an uncommon occurrence. 
To our knowledge, this study is the largest to report on 
the prognostic and predictive roles of concomitant KRAS 
mutation and copy number gain. We observed a consistent 
but non-significant trend towards worse LCSS (HR =1.34; 
95% CI, 0.83–2.17, P=0.232), DFS (HR =1.34; 95% CI, 
0.86–2.09, P=0.202) and OS (HR =1.59; 95% CI, 0.99–
2.54, P=0.055) in KRAS MUT + Gain patients relative to 
the WT + Neut/Loss group in the total population. The 
adenocarcinoma subgroup accounted for 73.2% (n=30) of the 
MUT + Gain patients, and although there was no significant 
prognostic effect noted, there appeared to be a similar trend 
towards worse OS (HR =1.40; 95% CI, 0.78–2.51, P=0.255). 
Sasaki et al. previously reported worse prognosis in NSCLC 
patients with both KRAS mutations and increased gene copy 
number when compared to KRAS WT patients with no 
increase in copy number; however, the study was limited by 
a small number of patients (n=8) (10). When we completed 
a similar comparison limited to only the two subgroups of 
KRAS MUT + Gain compared to WT + Neut/Loss, we also 
observed a significantly worse OS (HR =1.66; 95% CI, 1.02–
2.67, P=0.037) in KRAS MUT + Gain patients.
Singh et al. showed a significant correlation between 
KRAS gene amplification and KRAS-dependency. Moreover, 
increased gene copy number in KRAS-mutated tumors 
has been associated with elevated KRAS mRNA and 
protein expression (9,19). Perhaps there is a selection for 
copy number gain in tumors that already harbor a KRAS 
mutation, thereby conferring dependency on the KRAS 
oncogene for growth and survival. Studies suggest that 
KRAS oncogene addiction might play a role in early tumor 
initiation, with preclinical data showing development of 
early onset lung cancer in mice harboring mutations in 
KRAS (20). However, although KRAS mutations alone have 
been shown to promote lung tumor formation, additional 
genomic alterations are likely required for ongoing tumor 
progression (21). It is plausible that gene amplification 
Table 5 Predictive effect of KRAS mutation and copy number status on patient outcome in the adenocarcinoma subgroup (n=399) 
KRAS mutation and CNA
LCSS DFS OS
rHR [95% CI], P value P value* rHR [95% CI], P value P value* rHR [95% CI], P value P value*
Unadjusted model
KRASMUT, n=129 1.07 [0.58–1.99], 0.827 0.827 0.92 [0.51–1.63], 0.768 0.768 1.08 [0.58–2.03], 0.807 0.807
KRASWT, n=270 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=30 0.44 [0.14–1.39], 0.161 0.214 0.32 [0.11–0.95], 0.039 0.065 0.33 [0.11–1.03], 0.057 0.038
KRASMUT + Neut/Loss , n=99 1.43 [0.72–2.82], 0.306 1.29 [0.68–2.44], 0.439 1.60 [0.79–3.24], 0.191
KRASWT + Gain, n=16 1.92 [0.52–7.04], 0.325 2.16 [0.62–7.45], 0.225 2.60 [0.68–9.90], 0.161




KRASMUT, n=129 1.02 [0.54–1.92], 0.947 0.947 0.91 [0.50–1.64], 0.745 0.745 1.23 [0.64–2.34], 0.535 0.535
KRASWT, n=270 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=30 0.41 [0.13–1.33], 0.138 0.287 0.33 [0.11–0.99], 0.048 0.135 0.40 [0.13–1.26], 0.116 0.076
KRASMUT + Neut/Loss , n=99 1.38 [0.68–2.79], 0.367 1.27 [0.65–2.45], 0.486 1.76 [0.85–3.62], 0.126
KRASWT + Gain, n=16 1.46 [0.38–5.51], 0.580 1.60 [0.45–5.69], 0.471 2.12 [0.53–8.37], 0.286
KRASWT + Neut/Loss, n=254 
(reference)
1.00 1.00 1.00
*, interaction between variable and treatment. rHR, ratio of Hazard Ratio (rHR = HR(Chemo vs. Obs. in c)/HR(Chemo vs. Obs. in reference)); CNA, copy number 
aberration; CI, Confidence interval; LCSS, Lung cancer specific survival; DFS, disease free survival; OS, overall survival; WT, Wild-type; 
KRASMUT, KRAS mutant; Gain, copy number gain; Neut/Loss, copy number neutral/loss.
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is acquired in KRAS-dependent tumors to aid in tumor 
progression. Newnham et al. compared resected and 
recurrent NSCLC tumors and showed differential gene 
expression suggesting that concomitant KRAS mutations 
with CN gain might be implicated in tumor recurrence 
clinically (3). Moreover, preclinical models show that copy 
number gain in KRAS-mutated tumors appears to select for 
enhanced glycolytic metabolism (a compensatory mechanism 
to promote survival in tumors with mitochondrial defects), 
and might also be involved in increasing metastatic potential 
in lung cancer cells (21). Interestingly, we previously showed 
an increased risk (HR =2.76; 95% CI, 1.34–5.70, P=0.005) of 
developing a second primary cancer in patients with KRAS-
mutated tumors (1). The impact of concomitant KRAS 
mutation and gene copy number gain on cell survival, tumor 
recurrence, or the development of second primary cancers 
is unclear, and should be further investigated to determine if 
this might explain the observed trend towards worse survival 
in KRAS MUT + Gain patients. 
Variable responses to chemotherapy have been reported 
in KRAS-mutated tumors, and may depend on the subtype 
of the KRAS mutation (22,23). Garassino et al. reported a 
decreased response to cisplatin but increased response to 
paclitaxel and pemetrexed in KRAS G12C mutated tumors, 
whereas, KRAS G12D mutations appeared to be resistant 
to paclitaxel, and G12V mutations were highly sensitive 
to cisplatin but slightly more resistant to pemetrexed (23). 
Shepherd et al. previously reported variability in the effect 
of adjuvant chemotherapy on survival based on KRAS 
mutation subtypes, with worse DFS (HR =3.88; 95% 
CI, 1.44–10.46, P=0.007, interaction P=0.01) and OS 
(HR =5.78; 95% CI, 2.06–16.2, P=0.001, interaction 
P=0.002) observed in patients with KRAS codon 13 
mutations who received adjuvant chemotherapy (1). 
In addition, a potential deleterious effect of adjuvant 
chemotherapy was seen in patients with KRAS/TP53 co-
mutations when compared to WT/WT tumors (HR =2.49; 
95% CI, 1.10–5.64, P=0.03) (2). However, due to small 
patient numbers, these data require further validation. In 
contrast, we found that KRAS MUT + Gain was associated 
with a higher beneficial effect of chemotherapy on DFS 
(rHR =0.33; 95% CI, 0.11–0.99, P=0.048) compared to the 
WT + Neut/Loss group in adenocarcinoma patients, with 
a non-significant trend also seen for LCSS (rHR =0.41; 
95% CI, 0.13–1.33, P=0.14) and OS (rHR =0.40; 95% 
CI, 0.13–1.26, P=0.12) on multivariable analysis. A similar 
higher beneficial effect of chemotherapy on DFS and OS 
was also noted in KRAS MUT + Gain patients compared 
to WT + Neut/Loss patients in the total population, but 
this benefit may be driven by the adenocarcinoma subset. 
It is possible that KRAS MUT + Gain patients have an 
increased dependency on KRAS activation, which might 
lead to increased susceptibility to chemotherapy, leading 
to a decrease in risk for tumor recurrence. Whether this 
hypothesis might explain the higher beneficial effect of 
chemotherapy on DFS observed in our study is still to be 
determined, and additional studies are required to elucidate 
the mechanism by which KRAS MUT-Gain patients might 
be more responsive to chemotherapy.
There are limitations in this study. The KRAS mutation 
analyses were pooled from separate trials; therefore, there 
were differences in technique and laboratories used for 
testing. Secondly, we were unable to evaluate the predictive 
or prognostic role of different KRAS mutation subtypes in 
patients with KRAS mutations and CNA due to the small 
numbers in each group. This further highlights the need 
for pooled analyses to ensure adequate sample numbers 
for robust analyses for less common genetic alterations. 
Finally, we did not have complete smoking history data 
from all trials included in the current study; therefore, 
survival analyses adjusting for smoking status could not be 
completed due to the small sample size.
Conclusions
In summary, the current LACE-Bio analysis showed that 
concomitant KRAS mutations and copy number gain are 
rare, occurring in approximately 4% of NSCLC patients. 
Although not significant, there was a trend towards worse 
LCSS, DFS and OS in KRAS MUT + Gain patients relative 
to WT + Neut/Loss patients. In addition, concomitant 
KRAS mutation and CN gain appeared to predict for better 
DFS in adenocarcinoma patients treated with adjuvant 
chemotherapy, with a trend towards better LCSS and OS 
as well. However, these results could be driven by the small 
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Gain (N=41) Neutral/Loss (N=145)
N % N % N %
G12A 3 7.32 7 4.83 10 5.38
G12C 23 56.09 66 45.52 89 47.85
G12D 3 7.32 15 10.34 18 9.68
G12D, G12V 0 0.00 1 0.69 1 0.54
G12R 0 0.00 3 2.07 3 1.62
G12S 2 4.88 3 2.07 5 2.68
G12V 6 14.63 38 26.20 44 23.65
G13C 2 4.88 4 2.76 6 3.22
G13D 2 4.88 6 4.14 8 4.30
G13R 0 0.00 1 0.69 1 0.54
Missing 0 0.00 1 0.69 1 0.54
CNA, copy number aberration; Gain, copy number gain; Neut/Loss, copy number neutral/loss.




WT + Gain (N=58) MUT + Gain (N=25) MUT + Neut/Loss (N=82) Total (N=440)
N % N % N % N % N %
Smokers (Current/former) 244 88.73 54 93.10 25 100.0 74 90.24 397 90.23
Non-smokers 31 11.27 4 6.90 0 0.00 8 9.76 43 9.77
Table S3 Smoking status according to KRAS mutation and CNA status (n=440)
Smoking status
KRAS Mutation status KRAS CNA status
Total (N=440)
Wild Type (N=397) Mutant (N=107) Gain (N=83) Neutral/Loss (N=357)
N % N % N % N % N %
Smokers (Current/former) 298 89.49 99 92.52 79 95.18 318 89.08 397 90.23
Non-smokers 99 10.51 8 7.48 4 4.82 39 10.92 43 9.77
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Table S4 Prognostic effect of KRAS mutation and copy number status on patient outcome in adenocarcinoma subgroup (n=399) (fully adjusted 
models)
KRAS mutation and CNA
LCSS DFS OS
HR [95% CI], P value HR [95% CI], P value HR [95% CI], P value
KRASMUT, n=129 1.04 [0.76-1.43], 0.800 1.00 [0.74-1.35], 0.993 1.03 [0.75-1.42], 0.851
KRASWT, n=270 (reference) 1.00 1.00 1.00
KRASMUT + Gain, n=30 1.00 [0.55-1.83], 1.000 1.06 [0.60-1.84], 0.851 1.40 [0.78-2.51], 0.255
KRASMUT + Neut/Loss , n=99 1.09 [0.77-1.54], 0.610 1.02 [0.74-1.41], 0.892 0.98 [0.69-1.40], 0.933
KRASWT + Gain, n=16 1.59 [0.81-3.13], 0.176 1.56 [0.82-2.96], 0.177 1.41 [0.72-2.77], 0.318
KRASWT + Neut/Loss, n=254 (reference) 1.00 1.00 1.00
LCSS, Lung cancer specific survival; DFS, disease free survival; OS, overall survival; HR, Hazard Ratio; CI, Confidence interval; WT, Wild-
type; KRASMUT, KRAS mutant; Gain, copy number gain; Neut/Loss, copy number neutral/loss.
